Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Patents
  • Published:

Maximizing the commercial value of personalized therapeutics and companion diagnostics

Nature Biotechnology volume 31, pages 803–805 (2013)Cite this article

Subjects

Creating an intellectual property strategy that matches the co-development model and is tailored to the specific drug-diagnostic pair is essential to success.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Drug and diagnostic co-development pathway and patent filings.

References

  1. President's Council of Advisors on Science and Technology. Priorities for personalized medicine (2008).

  2. Naylor, S. & Cole, T. Overview of companion diagnostics in the pharmaceutical industry. Drug Discovery World Spring, 67–79 (2010).

    Google Scholar 

  3. FDA. Drug-diagnostic co-development concept paper (US Food and Drug Administration, 2004).

  4. FDA. Draft guidance for industry and Food and Drug Administration staff—in vitro companion diagnostic devices (US Food and Drug Administration, 2011).

  5. Ziegler, A. et al. Hum. Genet. 131, 1627–1638 (2012).

    Article  CAS  Google Scholar 

  6. Jørgensen, J. Drug Dev. Res. 73, 390–397 (2012).

    Article  Google Scholar 

  7. Jørgensen, J. et al. Oncologist 12, 397–405 (2007).

    Article  Google Scholar 

  8. Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 US, 132, S. Ct. 1289, 101 USPQ2d 1961 (2012).

  9. 21 USC section 355(b)(1) (2006).

  10. Mahn, T.G. Drug Labels: The New Orange Book. Update (The Food & Drug Law Institute) July/August, 8–12 (2006).

  11. 21 USC §355(j)(2)(A)(v) (2006).

  12. 21 CFR §314.94(a)(8)(iv) (2007).

  13. 21 CFR §314.127(a)(7) (2007).

Download references

Author information

Authors and Affiliations

  1. Cynthia H. Zhang is at Agilent Technologies, Singapore,

    Cynthia H Zhang

  2. Y. Philip Zhang is at Milstein Zhang and Wu LLC, Newton, Massachusetts, USA.,

    Y Philip Zhang

Authors
  1. Cynthia H Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y Philip Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y Philip Zhang.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, C., Zhang, Y. Maximizing the commercial value of personalized therapeutics and companion diagnostics. Nat Biotechnol 31, 803–805 (2013). https://doi.org/10.1038/nbt.2679

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2679

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research